- Home
- OFS vs MCRB Comparison
OFS vs MCRB Comparison
Compare OFS & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OFS | MCRB |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 47.4M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OFS | MCRB |
|---|---|---|
| Price | $3.57 | $4.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 51.4K | ★ 53.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $4.32 |
| 52 Week High | $8.99 | $29.98 |
Technical Indicators
Market Signals| Indicator | OFS | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 48.13 | 36.18 |
| Support Level | $3.26 | N/A |
| Resistance Level | $3.85 | $5.65 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 46.88 | 10.86 |
Price Performance
Historical ComparisonAbout OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.